Secukinumab delivers better QoL improvement in psoriasis than etanercept
Quality-of-life (QoL) improvements in patients with psoriasis are faster and greater with secukinumab than etanercept treatment, according to a recent study.
The analysis centred on the effect of secukinumab treatment on patient-reported health-related QoL as evaluated by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. Researchers compared between secukinumab and etanercept the proportion of participants (n=1,470) achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response and sustained DLQI score 0/1 response up to week 52.
Of the participants, 1,144 received secukinumab and 326 etanercept. Patients in the secukinumab group had significantly higher DLQI score 0/1 response rates than those in the etanercept group at week 24. A significantly shorter median time to DLQI score 0/1 response was seen in secukinumab vs etanercept (12 vs 24 weeks; p<0.01).
The DLQI score 0/1 response was achieved by majority of secukinumab-treated patients at week 24. This was sustained through week 52, along with a 90- to 100-percent decrease in the Psoriasis Area and Severity Index total score response.
The study was limited by the insufficient placebo comparisons during the maintenance period due to rerandomization at week 12, according to researchers.
Findings from a prior research showed that patients receiving secukinumab have greater improvements and more effective relief from psoriasis impact on daily activities and personal relationships than those receiving etanercept. [J Dermatolog Treat 2016;21:1-6]
“Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment,” researchers said.